Ticker Launch
Sign inTry it free

IPO · VRAX

Virax Biolabs Group Ltd

Formerly Virax Biolabs (Cayman) Ltd

Virax Biolabs Group Ltd (VRAX) priced its initial public offering on Jul 21, 2022 at $5.00 per share, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $56.9M. Loeb & Loeb, Ogier, Wong Tan & Molly Lim and Zhong Lun advised the company.

Virax Biolabs Group Ltd develops immunological diagnostic tools, including the Virax Immune profiling technique and a T-cell in-vitro diagnostic test aimed at viral diseases. Its ViraxClear brand also distributes COVID-19 test kits sourced from third parties.

Status
IPO
Ticker
VRAX
Exchange
Nasdaq Capital Market
Priced
Jul 21, 2022
IPO price
$5.00
Market cap at IPO price
$56.9M
First filed
Mar 18, 2022
Company counsel
Loeb & Loeb, Ogier, Wong Tan & Molly Lim and Zhong Lun
Sector
Biotech & pharma
Country / state
United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.

More on this listing for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other Biotech & pharma IPOs in 2022